Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen  receptor-positive/HER2-negative breast cancer: results of a prospective observational study

R. V. Orlova; Орлова Р. В.; A. A. Vakhitova; Вахитова А. А.; E. E. Topuzov; Топузов Э. Э.; M. I. Gluzman; Глузман М. И.; E. L. Serikova; Серикова Е. Л.; M. A. Petrenko; Петренко М. А.; L. V. Bembeeva; Бембеева Л. В.; A. V. Krasnoperova; Красноперова А. В.; T. N. Kotkova; Коткова Т. Н.; A. V. Androsova; Андросова А. В.; I. O. Sharvashidze; Шарвашидзе И. О.

doi:10.17650/3034-2473-2024-1-3-13-25

Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study

Authors: Orlova R.V.¹^,2, Vakhitova A.A.², Topuzov E.E.¹^,2^,3, Gluzman M.I.¹^,2, Serikova E.L.², Petrenko M.A.², Bembeeva L.V.², Krasnoperova A.V.², Kotkova T.N.², Androsova A.V.¹^,2, Sharvashidze I.O.²
Affiliations:
1. Saint Petersburg State University
2. Saint Petersburg City Clinical Oncology Dispensary
3. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Issue: Vol 1, No 3 (2024)
Pages: 13-25
Section: ORIGINAL REPORTS
Published: 22.01.2025
URL: https://stio.abvpress.ru/jour/article/view/36
DOI: https://doi.org/10.17650/3034-2473-2024-1-3-13-25
ID: 36

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around the world, it is extremely important to address the issue of indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well as the scope and regimens of treatment. The article presents the results of our own study, considers the problems of toxicity and tolerability of dose-dense and standard NACT regimens.

Aim. To study the tolerability of dose-dense and standard NACT regimens.

Materials and methods. The prospective study included 109 patients. 53 patients received dose-dense NACT as preoperative treatment, 56 – the standard NACT regimen.

Results. In dose-dense NACT, the frequency and severity of anemia (p = 0.038), hepatotoxicity (p <0.001), peripheral polyneuropathy (p <0.001) increased, but the frequency of delayed start of the cycle in general (p = 0.012) and delay due to neutropenia (p <0.001) decreased.

Conclusion. When planning preventive chemotherapy in the treatment of breast cancer (NACT or adjuvant chemotherapy), it is necessary to take into account not only the oncological results in increasing recurrence-free and overall survival, but also the tolerability of therapy.

Keywords

breast cancer, dose-dense neoadjuvant chemotherapy, standard neoadjuvant chemotherapy, granulocyte colony-stimulating factor

About the authors

R. V. Orlova

Saint Petersburg State University; Saint Petersburg City Clinical Oncology Dispensary

ORCID iD: 0000-0003-4447-9458

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

Russian Federation

A. A. Vakhitova

Saint Petersburg City Clinical Oncology Dispensary

Author for correspondence.
Email: alberdovna@mail.ru
ORCID iD: 0000-0003-1321-3657

Almira Alberdovna Vakhitova

56 Prospekt Veteranov, Saint Petersburg 198255

Russian Federation

E. E. Topuzov

Saint Petersburg State University; Saint Petersburg City Clinical Oncology Dispensary; I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-2105-2251

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

41 Kirochnaya St., Saint Petersburg 191015

Russian Federation